Table 3 Risk of all cancers in ranitidine users compared with that in other H2RA users by cumulative exposure duration and dose in the propensity score matched cohort.
From: Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea
No. of events | 1000 person years | Incidence rate per 1000 person years (95% CI) | Crude HR (95% CI) | Adjusted HR (95% CI)† | |
|---|---|---|---|---|---|
Cumulative exposure duration (days) | |||||
Other H2RAs | 216 | 72.9 | 3.0 (2.6–3.4) | ||
Ranitidine | |||||
≤ 14 days | 93 | 37.2 | 2.5 (2.0–3.1) | 0.88 (0.69–1.12) | 0.94 (0.74–1.20) |
15–30 days | 44 | 13.4 | 3.3 (2.4–4.4) | 1.11 (0.80–1.53) | 1.11 (0.80–1.53) |
31–60 days | 34 | 8.6 | 4.0 (2.7–5.5) | 1.30 (0.91–1.87) | 1.24 (0.86–1.78) |
61–90 days | 10 | 3.2 | 3.1 (1.5–5.7) | 1.02 (0.54–1.93) | 0.85 (0.45–1.60) |
91–180 days | 14 | 3.2 | 4.4 (2.4–7.3) | 1.41 (0.82–2.43) | 1.18 (0.69–2.03) |
> 180 days | 10 | 4.3 | 2.3 (1.1–4.3) | 0.75 (0.40–1.42) | 0.53 (0.28–1.01) |
Cumulative dose (defined daily dose, DDD) | |||||
Other H2RAs | 216 | 72.9 | 3.0 (2.6–3.4) | ||
Ranitidine | |||||
< 6 DDD | 65 | 25.0 | 2.6 (2.0–3.3) | 0.92 (0.70–1.22) | 1.01 (0.77–1.34) |
6–50 DDD | 109 | 35.0 | 3.1 (2.6–3.8) | 1.05 (0.84–1.33) | 1.05 (0.83–1.32) |
> 50 DDD | 31 | 10.0 | 3.1 (2.1–4.4) | 1.00 (0.69–1.46) | 0.78 (0.53–1.14) |
